hotspot -WSS

hotspot

author：knowledge 2025-09-30 22:06:35 - browse：17656

Verve Therapeutics said Sunday that the first 10 people to receive a one-time treatment powered by a form of CRISPR called base editing showed reductions in bad cholesterol levels — study results that are preliminary but signal the potential for gene-editing treatments to benefit people with an inherited type of cardiovascular disease.

Three of the study participants treated with potentially therapeutic doses of the Verve drug, called VERVE-101, showed reductions in LDL-C levels of 39%, 48%, and 55%, respectively. The latter patient’s decline in so-called “bad” cholesterol was maintained for six months.

The Verve-101 study results were presented at the American Heart Association conference and are the first data in patients from a therapy that uses base editing to change individual letters of DNA. Verve licensed the base-editing technology from Beam Therapeutics.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： DIEP, the 'gold standard' of breast reconstruction, is under threat
Next article： Dark money group runs ads on China biotech bill

WSS

For one rare type of lung cancer, Pfizer pill reduces progression by 81%

What will save rural psychiatry services? Higher Medicaid payments

For one rare type of lung cancer, Pfizer pill reduces progression by 81%

Addiction doctors spar with methadone clinics over legislation

NIH documents show early flaws of $1.6 billion long Covid program

Merus drug and Keytruda shrank tumors in patients with head and neck cancer

focus

hotspot

focus

Hollywood unions extend contract negotiations for actors

With trial win, GSK could get blood cancer drug back on market

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Change Healthcare can notify patients about the breach, HHS says

Peter Hotez and the public health issue of online harassment

Merus drug and Keytruda shrank tumors in patients with head and neck cancer

Novavax promises a turnaround & Lilly roils the obesity market

Merck to buy EyeBio, maker of eye drug, as it grows pipeline

Hollywood unions extend contract negotiations for actors

Readout Newsletter: Moderna bird flu vaccine, Biohaven, ASCO

focus

Latest bird flu infection made farmworker sicker than earlier cases

Readout Newsletter: Moderna bird flu vaccine, Biohaven, ASCO

Health insurers say they are turning to AI to cut costs, improve care

Shifting the focus from loneliness to social health

Let's speed up science by embracing open access publishing

Ionis drug prevents swelling attacks due to hereditary angioedema

leisure time

knowledge

leisure time

focus